These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 9798204)
1. Irinotecan may extend survival in people with metastatic colorectal cancer. Oncology (Williston Park); 1998 Oct; 12(10):1512. PubMed ID: 9798204 [No Abstract] [Full Text] [Related]
2. [Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer]. Krieger G Strahlenther Onkol; 2001 Jun; 177(6):316-8. PubMed ID: 11446323 [No Abstract] [Full Text] [Related]
3. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. Mitry E; Ducreux M; Rougier P Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083 [TBL] [Abstract][Full Text] [Related]
4. Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice. Cunningham D Semin Oncol; 1999 Feb; 26(1 Suppl 5):1-5. PubMed ID: 10213008 [TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486 [TBL] [Abstract][Full Text] [Related]
6. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. Van Cutsem E; Blijham GH Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010 [TBL] [Abstract][Full Text] [Related]
7. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Cunningham D; Pyrhönen S; James RD; Punt CJ; Hickish TF; Heikkila R; Johannesen TB; Starkhammar H; Topham CA; Awad L; Jacques C; Herait P Lancet; 1998 Oct; 352(9138):1413-8. PubMed ID: 9807987 [TBL] [Abstract][Full Text] [Related]
8. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Cunningham D; Glimelius B Semin Oncol; 1999 Feb; 26(1 Suppl 5):6-12. PubMed ID: 10213009 [TBL] [Abstract][Full Text] [Related]
9. Irinotecan: toward clinical end points in drug development. Pazdur R Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086 [TBL] [Abstract][Full Text] [Related]
10. Comparing irinotecan with best supportive care and infusional 5-fluorouracil: a critical evaluation of the results of two randomized phase III trials. Wilke HJ Semin Oncol; 1999 Feb; 26(1 Suppl 5):21-3. PubMed ID: 10213011 [TBL] [Abstract][Full Text] [Related]
11. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Rougier P; Van Cutsem E; Bajetta E; Niederle N; Possinger K; Labianca R; Navarro M; Morant R; Bleiberg H; Wils J; Awad L; Herait P; Jacques C Lancet; 1998 Oct; 352(9138):1407-12. PubMed ID: 9807986 [TBL] [Abstract][Full Text] [Related]
12. [Irinotecan in the second-line therapy of metastatic colorectal carcinoma]. Petrasch S; Dörr T; Kemmeries G Z Gastroenterol; 1999 Jun; 37(6):575-7. PubMed ID: 10427662 [No Abstract] [Full Text] [Related]
13. Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage. Prescrire Int; 2001 Apr; 10(52):41-3. PubMed ID: 11718156 [TBL] [Abstract][Full Text] [Related]
14. Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. Goldberg RM; Erlichman C Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):59-63. PubMed ID: 9726093 [TBL] [Abstract][Full Text] [Related]
15. What's new in ... colorectal cancer. Meaningful progress in therapy options. Polansky M; Ross AC JAAPA; 2009 Apr; 22(4):51-2. PubMed ID: 19452823 [No Abstract] [Full Text] [Related]
20. Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure. Schmitt C; Blijham G; Jolain B; Rougier P; Van Cutsem E Anticancer Drugs; 1999 Jul; 10(6):617-23. PubMed ID: 10885910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]